Evidence map›Paper›PMID 30863049›Full record

ArticleInternational journal of nanomedicine2019

Lipo-PEG-PEI complex as an intracellular transporter for protein therapeutics.

Yu-Ling Lin, Chia-Hung Chen, Yen-Ku Liu, Tse-Hung Huang, Nu-Man Tsai, Shey-Cherng Tzou, Kuang-Wen Liao

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. EncapsulatedInternational journal of nanomedicine · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yu-Ling LinAgricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan, ROC.
Chia-Hung ChenDepartment of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan, ROC, liaonms@pchome.com.tw; sctzou@gmail.com.
Yen-Ku LiuDepartment of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan, ROC, liaonms@pchome.com.tw; sctzou@gmail.com.
Tse-Hung HuangDepartment of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan, ROC.
Nu-Man TsaiSchool of Medical Laboratory and Biotechnology, Chung Shan Medical University.
Shey-Cherng TzouDepartment of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan, ROC, liaonms@pchome.com.tw; sctzou@gmail.com.
Kuang-Wen LiaoDepartment of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan, ROC, liaonms@pchome.com.tw; sctzou@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProtein or peptide drugs are emerging therapeutics for treating human diseases. However, current protein drugs are typically limited to acting on extracellular/cell membrane components associated with the diseases, while intracellular delivery of recombinant proteins replaces or replenishes faulty/missing proteins and remains inadequate. In this study, we developed a convenient and efficient intracellular protein delivery vehicle. MATERIALS AND

methodsA cationic liposomal polyethylenimine and polyethylene glycol complex (LPPC) was developed to noncovalently capture proteins for protein transfer into cells via endocytosis. β-glucuronidase (βG) was used in vitro and in vivo as a model enzyme to demonstrate the enzymatic activity of the intracellular transport of a protein.

resultsThe endocytosed protein/LPPC complexes escaped from lysosomes, and the bound protein dissociated from LPPC in the cytosol. The enzymatic activity of βG was well preserved after intracellular delivery in vitro and in vivo.

conclusionUsing LPPC as an intracellular protein transporter for protein therapeutics, we illustrated that LPPC may be an effective and convenient tool for studying diseases and developing therapeutics.

Indexed as

3T3 CellsAdsorptionAnimalsCattleCell DeathFluorescein-5-isothiocyanateFluorescenceGlucuronidaseGreen Fluorescent ProteinsHep G2 CellsHumansIntracellular SpaceLiposomesMiceMice, Inbred BALB CParticle Sizeenhanced green fluorescent proteinFluorescein-5-isothiocyanateGlucuronidaseGreen Fluorescent ProteinsLiposomespoly(ethylene glycol)-co-poly(ethyleneimine)Polyethylene GlycolsPolyethyleneimineProteinsSerum Albumin, BovineEGFPendocytosisenhanced green fluorescent proteinintracellular protein deliveryliposomal polyethylenimine and polyethylene glycol complexLPPCβ-glucuronidase

Identifiers

PMID30863049
PMCPMC6391157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.